Ascendis Pharma A/S (ASND) Jefferies Global Healthcare Conference 2026 November 17, 2026 6:30 AM EST.
Jan Mikkelsen - President, CEO, Member of Executive Board & Executive DirectorScott Smith - CFO, Executive VP & Member of Executive Board.
Faisal Khurshid - Jefferies LLC, Research Division.
Faisal KhurshidJefferies LLC, Research Division.
All right. Good morning, everyone. Thank you for joining us here in nice and rainy London. My name is Faisal Khurshid. I'm one of the senior biotech analysts here at Jefferies. Really pleased to have with us today management team of Ascendis Pharma. I have on stage with me Jan Mikkelsen, CEO; Scott Smith, CFO of the firm. But let's get right to it.
Faisal KhurshidJefferies LLC, Research Division.
I mean, you guys just reported nice third quarter earnings last week. You have 2 growth products. Maybe we can just start with some of the highlights from earnings. I don't know, Jan, if you want to start or Scott?
Jan MikkelsenPresident, CEO, Member of Executive Board & Executive Director.
I think Scott should start today.
Scott SmithCFO, Executive VP & Member of Executive Board.
Start with the question or start with the FLS? Okay. Yes. So thanks for the invitation for the conference here, and it's a really neat setting to see everybody packed in here. As you alluded to, we just reported our 3Q results last week. So the conference is timely. We had pretty good revenue growth, I would say, 90% or so year-over-year to EUR 366 million, strong growth across the portfolio. We also announced, which Jan, I'm sure, will be interested to go into detail on.
And across -- from an OpEx perspective, we had about EUR 230 million of OpEx, leading to pretty good, I would say, almost industry-leading.
